| Nome |
# |
|
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial, file e27ce42a-9a18-2581-e053-d805fe0acbaa
|
1.962
|
|
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth, file e27ce42c-7e04-2581-e053-d805fe0acbaa
|
749
|
|
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer, file e27ce426-f447-2581-e053-d805fe0acbaa
|
671
|
|
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer, file e27ce42c-ac40-2581-e053-d805fe0acbaa
|
403
|
|
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies, file e27ce426-f0f2-2581-e053-d805fe0acbaa
|
313
|
|
Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer, file e27ce42b-4659-2581-e053-d805fe0acbaa
|
301
|
|
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer, file e27ce427-2d1b-2581-e053-d805fe0acbaa
|
291
|
|
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma, file e27ce42b-34b3-2581-e053-d805fe0acbaa
|
265
|
|
Minimal residual disease in breast cancer: in blood veritas., file e27ce426-f514-2581-e053-d805fe0acbaa
|
256
|
|
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor, file e27ce42b-ad33-2581-e053-d805fe0acbaa
|
236
|
|
Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer, file e27ce426-d50c-2581-e053-d805fe0acbaa
|
223
|
|
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer, file e27ce42a-9432-2581-e053-d805fe0acbaa
|
215
|
|
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations, file e27ce428-9706-2581-e053-d805fe0acbaa
|
204
|
|
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer, file e27ce42b-fd7d-2581-e053-d805fe0acbaa
|
204
|
|
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer, file e27ce428-ee7a-2581-e053-d805fe0acbaa
|
184
|
|
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance., file e27ce427-09b8-2581-e053-d805fe0acbaa
|
162
|
|
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology, file e27ce42e-7735-2581-e053-d805fe0acbaa
|
149
|
|
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, file e27ce428-f6ea-2581-e053-d805fe0acbaa
|
145
|
|
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer, file e27ce42c-4ba9-2581-e053-d805fe0acbaa
|
143
|
|
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition, file e27ce42a-d37f-2581-e053-d805fe0acbaa
|
129
|
|
Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients, file e27ce42a-d380-2581-e053-d805fe0acbaa
|
129
|
|
How liquid biopsies can change clinical practice in oncology, file e27ce42f-a2de-2581-e053-d805fe0acbaa
|
104
|
|
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer, file e27ce429-176a-2581-e053-d805fe0acbaa
|
95
|
|
TAS-120 overcomes resistance to atp-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma, file e27ce42f-6ed8-2581-e053-d805fe0acbaa
|
86
|
|
MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer, file e27ce429-c87b-2581-e053-d805fe0acbaa
|
85
|
|
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer, file e27ce427-3a7d-2581-e053-d805fe0acbaa
|
83
|
|
Tumor heterogeneity and Lesion-Specific response to targeted therapy in colorectal cancer, file e27ce429-1433-2581-e053-d805fe0acbaa
|
80
|
|
Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer, file e27ce42b-6238-2581-e053-d805fe0acbaa
|
76
|
|
Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours, file e27ce42e-2a00-2581-e053-d805fe0acbaa
|
71
|
|
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor, file e27ce42b-c004-2581-e053-d805fe0acbaa
|
61
|
|
null, file e27ce430-cb75-2581-e053-d805fe0acbaa
|
53
|
|
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers, file e27ce42e-9715-2581-e053-d805fe0acbaa
|
38
|
|
Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor, file e27ce42c-29ea-2581-e053-d805fe0acbaa
|
34
|
|
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer., file e27ce426-e096-2581-e053-d805fe0acbaa
|
22
|
|
The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer, file e27ce429-add3-2581-e053-d805fe0acbaa
|
20
|
|
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer, file e27ce42d-8306-2581-e053-d805fe0acbaa
|
20
|
|
Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-Amplified esophagogastric cancer, file e27ce428-d295-2581-e053-d805fe0acbaa
|
16
|
|
Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours, file e27ce42e-e4b0-2581-e053-d805fe0acbaa
|
16
|
|
Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer, file e27ce433-9827-2581-e053-d805fe0acbaa
|
16
|
|
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer, file e27ce431-a6db-2581-e053-d805fe0acbaa
|
9
|
|
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth, file e27ce42c-77f6-2581-e053-d805fe0acbaa
|
7
|
|
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer, file e27ce432-5e80-2581-e053-d805fe0acbaa
|
7
|
|
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology, file e27ce42e-7a1f-2581-e053-d805fe0acbaa
|
6
|
|
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer, file a75404be-0edf-4467-aa2d-1269f4af5fb3
|
5
|
|
Liquid biopsies to evaluate early therapeutic response in colorectal cancer, file e27ce428-d0ae-2581-e053-d805fe0acbaa
|
5
|
|
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers, file e27ce42b-f0fd-2581-e053-d805fe0acbaa
|
5
|
|
The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer, file e27ce429-add4-2581-e053-d805fe0acbaa
|
3
|
|
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial, file e27ce42a-9a17-2581-e053-d805fe0acbaa
|
3
|
|
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer, file e27ce42c-4688-2581-e053-d805fe0acbaa
|
3
|
|
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer, file e27ce42c-a14e-2581-e053-d805fe0acbaa
|
3
|
|
Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know, file e27ce430-8ec5-2581-e053-d805fe0acbaa
|
3
|
|
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations, file e27ce432-5371-2581-e053-d805fe0acbaa
|
3
|
|
Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer, file e27ce426-d50b-2581-e053-d805fe0acbaa
|
2
|
|
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer, file e27ce427-39fa-2581-e053-d805fe0acbaa
|
2
|
|
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer, file e27ce428-9ee6-2581-e053-d805fe0acbaa
|
2
|
|
Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer, file e27ce42f-9c9d-2581-e053-d805fe0acbaa
|
2
|
|
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies, file e27ce427-cbbc-2581-e053-d805fe0acbaa
|
1
|
|
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations, file e27ce428-9900-2581-e053-d805fe0acbaa
|
1
|
|
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer, file e27ce429-13c3-2581-e053-d805fe0acbaa
|
1
|
|
Tumor heterogeneity and Lesion-Specific response to targeted therapy in colorectal cancer, file e27ce429-142a-2581-e053-d805fe0acbaa
|
1
|
|
MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer, file e27ce429-c87c-2581-e053-d805fe0acbaa
|
1
|
|
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer, file e27ce429-cb90-2581-e053-d805fe0acbaa
|
1
|
|
Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients, file e27ce42a-a40b-2581-e053-d805fe0acbaa
|
1
|
|
Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor, file e27ce42b-e474-2581-e053-d805fe0acbaa
|
1
|
|
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer, file e27ce42c-3b7a-2581-e053-d805fe0acbaa
|
1
|
|
Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer, file e27ce42d-e4ae-2581-e053-d805fe0acbaa
|
1
|
|
TAS-120 overcomes resistance to atp-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma, file e27ce42f-6ed9-2581-e053-d805fe0acbaa
|
1
|
|
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers, file e27ce42f-98ed-2581-e053-d805fe0acbaa
|
1
|
|
How liquid biopsies can change clinical practice in oncology, file e27ce42f-a2df-2581-e053-d805fe0acbaa
|
1
|
|
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth, file e27ce432-4e12-2581-e053-d805fe0acbaa
|
1
|
|
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer, file e27ce432-57be-2581-e053-d805fe0acbaa
|
1
|
|
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer, file e27ce432-5d0a-2581-e053-d805fe0acbaa
|
1
|
|
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology, file e27ce432-5ec5-2581-e053-d805fe0acbaa
|
1
|
| Totale |
8.397 |